Product Name?: (5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone (Dapagliflozin Intermediate 2)
?CAS No.?: 461432-22-4

?? ?Product Overview?
A high-purity pharmaceutical intermediate for synthesizing ?Dapagliflozin? (CAS 461432-26-8), a leading ?SGLT2 inhibitor? used to treat type 2 diabetes by reducing glucose reabsorption in kidneys. With ?≥95% purity? (HPLC-certified), it ensures reliable quality in API manufacturing and R&D for diabetes therapeutics. Available in bulk quantities (1kg–25kg) with industrial-grade packaging.

?? ?Key Advantages?
? ?High Purity?: ≥95% (HPLC/GC-certified), ensuring low impurity levels for API synthesis.
?? ?Bulk Availability?: Customizable packaging (25kg/drum) for industrial and lab-scale use.
?? ?Strategic Role?: Critical intermediate for Dapagliflozin, a $3.5B+ market drug with growing demand.

?? ?Applications?

1. ?Diabetes Drug Production?: Key building block for Dapagliflozin API synthesis.

2. ?Pharmaceutical R&D?: Supports development of novel SGLT2 inhibitors.

3. ?Chemical Export?: Widely used in global pharmaceutical and reagent markets.

?? ?Quality Certification?

• ?Testing Standards?: HPLC, GC, and NMR analysis.

• ?Compliance?: Meets ISO 9001 and enterprise export specifications.

?? ?Market Trends?
The global SGLT2 inhibitor market is projected to grow at ?9.2% CAGR (2025–2030)? due to rising diabetes prevalence and patent expirations (2026–2028). Asia-Pacific dominates generic API production, with suppliers offering ?GMP-ready intermediates? gaining traction in cost-sensitive markets.